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Abstract 
In the past nearly 20 years, organ-sparing when no apparent viable tumour is present after neoadjuvant therapy has 
taken an increasingly relevant role in the therapeutic management of locally-advanced rectal cancer patients. The 
decision to include a patient or not in a “Watch-and-Wait” program relies mainly on endoscopic assessment by skilled 
surgeons, and MR imaging by experienced radiologists. Strict surveillance using the same modalities is required, 
given the chance of a local regrowth is of approximately 25–30%, almost always surgically salvageable if caught early. 
Local regrowths occur at the endoluminal aspect of the primary tumour bed in almost 90% of patients, but the rest 
are deep within it or outside the rectal wall, in which case detection relies solely on MR Imaging. In this educational 
review, we provide a practical guide for radiologists who are, or intend to be, involved in the re-staging and follow-
up of rectal cancer patients in institutions with an established “Watch-and-Wait” program. First, we discuss patient 
preparation and MR imaging acquisition technique. Second, we focus on the re-staging MR imaging examination and 
review the imaging findings that allow us to assess response. Third, we focus on follow-up assessments of patients 
who defer surgery and confer about the early signs that may indicate a sustained/non-sustained complete response, 
a rectal/extra-rectal regrowth, and the particular prognosis of the “near-complete” responders. Finally, we discuss our 
proposed report template.
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Key points
• MR Imaging is one of the pillars for the selection and 
follow-up of patients when “Watch-and-Wait” is an 
option.
• Radiologists participating in “Watch-and-Wait” pro-
grams should be familiar with the imaging findings 
that indicate a poor/incomplete response, a complete 
response and a “near-complete” response.
• Given deep rectal and extra-rectal regrowth detec-
tion relies on MR imaging only, radiologists should 
combine a high index of suspicion with a high preci-
sion, to propel salvage surgery only when needed.
Introduction
The concept of “locally-advanced rectal cancer” is intrin-
sically linked with a clinical indication for neoadjuvant 
therapy (NAT). It traditionally applies to all clinically 
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and other centres across Europe criteria may be more 
strict [1, 2]. NAT regimens were initially designed with 
the sole purpose of downsizing/downstaging tumours in 
order to increase the likelihood of an R0 resection and 
diminish the risk of local recurrence [3], but the 10–25% 
pathologic complete response (pCR) rates have led cli-
nicians to question the utility of radical surgery itself in 
such cases [4]. In fact, the real pCR odds may be even 
higher, given most patients included in reported stud-
ies were operated at 6–8 weeks while pCR rates increase 
significantly when the interval to surgery is lengthened 
to > 12 weeks post-radiotherapy (RT) [5]. This means that 
if patients are re-staged and no signs of tumour persis-
tence are present, deferral of surgery may be a reasonable 
option, and “Watch-and-Wait” (W&W) programs have 
grown increasingly available and popular during the past 
almost 20  years [4]. For willing and able patients, this 
decision is largely based on re-staging rectal endoscopy 
and MR imaging assessments [6]. Strict follow-up after-
wards is founded on the same grounds [6]. The overall 
survival of clinical complete responders appears similar 
to that of patients who undergo surgery and have a pCR 
[7]. Furthermore, out of the approximately 30% clinical 
complete responders who later on present with tumour 
regrowth, 95% are salvageable [8]. However, patients 
with local regrowth may present with a higher rate of 
distant metastatic disease compared to sustained clini-
cal complete responders [9]. Whether this phenomenon 
is a reflection of the tumour biology or a consequence of 
an uncontrolled primary is not yet known [9]. Magnetic 
resonance (MR) imaging, as part of response assessment, 
should aim to distinguish “true” complete responders 
from patients with persistent, even if subclinical, disease, 
who need surgery for cure as early as possible. This edu-
cational review has three purposes: the first is to provide 
radiologists with the main relevant information to re-
stage rectal cancer patients after NAT based on stand-
ard MR imaging; the second is to guide them through 
W&W follow-up MR imaging assessments in order to 
detect pelvic regrowths /recurrences as early as possible; 
the third is to present and discuss our proposed report 
template.
MR imaging preparation and acquisition technique
Before MR imaging acquisition, there are two prepara-
tory steps which may significantly contribute to improve 
image quality. The first step is to ask patients to perform a 
small enema for rectal emptying before entering the MR 
equipment [10]. The second is to administer a spasmo-
lytic agent such as butylscopolamine or glucagon before 
acquisition [10]. These two preparation steps are meant 
to minimise susceptibility artefacts due to air content 
and movement artefacts from peristalsis, respectively, 
given both adversely impact image interpretation, of dif-
fusion-weighted imaging (DWI) in particular [10]. They 
are considered optional according to both ESGAR and 
SAR guidelines [11, 12]. When despite these measures 
patients still present with rectal air at tumour bed level 
and if they agree, a lubricated cannula can be inserted 
in the rectum for further emptying, and then removed 
before acquisition.
The use of endoluminal gel is not advocated routinely 
because distension of the rectum may result in misinter-
pretation of the distance between  the tumour  bed and 
circumferential resection margin (CRM), an essential re-
staging information when surgery is a possibility [13]. If 
considered useful, gel should not exceed 60 ml to prevent 
excessive compression of the mesorectal fat [14].
Regarding technique, examinations should be per-
formed on a 1.5T or 3T equipment using an external coil 
[11, 12]. 2D high-resolution T2-WI with a slice thickness 
≤3 mm should be acquired in sagittal, axial and coronal 
planes, the two latter angulated perpendicular and paral-
lel to the long axis of the tumour, respectively [11, 12]. 
In low tumours, additional high-resolution T2-WI angu-
lated perpendicular and parallel to the anal canal may be 
acquired to better assess its involvement [11, 12]. A DWI 
acquisition including a high b value (≥ 800) should also 
be acquired, preferably with the same orientation as the 
axial high resolution T2-WI to ease  finding co-localisa-
tion [11, 12]. Intravenous paramagnetic contrast admin-
istration is not routinely recommended [11, 12] but it 
may be useful in particular situations such as pelvic sep-
sis or fistulisation. Detailed acquisition protocols for our 
1.5T and 3T Ingenia Philips Healthcare®, Best, The Neth-
erlands clinical scanners are provided in Table 1.
Re‑staging after neoadjuvant therapy
The issue of when to first assess tumour response is 
controversial. While the rate of pCR may increase after 
12 weeks post-RT [5] some surgical teams are reluctant 
to operate beyond 8 weeks due to concerns about radia-
tion-induced pelvic fibrosis and related surgical compli-
cations [15], which implies identifying poor/incomplete 
responders early. To move the decision timepoint from 
6–8 weeks to 10–12 weeks post-RT may have no impact 
on surgery-related morbidity or mortality [16], and the 
extended period of surveillance may allow the start of 
consolidation chemotherapy on metastatic high-risk 
patients that may benefit from total NAT.
Although clinical and laboratory evaluation is rel-
evant, re-staging relies heavily on rectal endoscopy and 
MR imaging. If the two are to be performed on the same 
day and given endoscopy requires the insufflation of air 
into the rectum, to perform MR imaging first may be 
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preferable in order to minimise air-induced susceptibility 
artefacts.
Endoscopic assessment [16] may be standardised 
according to a 5-point ordinal scale defined by the inter-
national W&W database consortium: responses may be 
graded, from best to worse response, as 0 (flat white scar 
with telangiectasia), 1 (shallow ulcer/red scar), 2 (ulcer-
ated residual lesion or adenomatous residual mucosal 
abnormality), 3 (excavated ulcer with elevated edges) or 4 
(persistent infiltrative lesion).
To identify the incomplete/poor responders
Approximately 20% of locally advanced rectal cancer 
patients show a poor response to neoadjuvant therapy, 
which may imply a shift in the neoadjuvant treatment 
scheme or early surgery [17, 18]. Poor responses gener-
ally present with endoscopic gradings of 3–4 and on MR 
imaging are characterised by (Fig. 1a–c):
1. Little reduction in tumour size
A tumour volume reduction below 70%, as based on 
slice-by-slice segmentation on T2-WI, is associated with 
a poor response [19–22]. Given tumour volume meas-
urement is difficult and time-consuming, cranio-caudal 
length was suggested as an alternative [12]. Based on 
mrRECIST, less than 30% reduction in cranio-caudal 
tumour length is associated with a poor response [23]. 
However, this criteria was not validated prospectively 
[24].
2. MR Tumour regression grades (mrTRG) 3–5
MrTRG is an ordinal scale developed by Patel et  al.to 
assess response on MR T2-WI in a parallel manner to 
the Mandard pathological TRG score [23, 25] and is pre-
sented in Table 2 [18].
There are multiple ordinal scales in the literature that 
represent variations or adaptations to it but in general, 
when T2-WI intermediate “tumour” signal predominates 
over hypointense fibrosis or clear hyperintense “acel-
lular mucin” (mrTRG4-5, mrTRG5 hardly ever being 
observed in our experience), a poor response is assumed, 
and the 3-year disease free survival is 21% inferior com-
pared to favourable mrTRG1-3s [23]. mrTRG3 may fall 
on the “good side” regarding long-term outcome [26] but 
the likelihood of a pCR or cCR when T2-intermediate 
clearly “tumoural” signal remains after neoadjuvant treat-
ment is low, and it is therefore considered a sign of an 
incomplete response [27].
3. Significant restriction to diffusion on Diffusion-
weighted Imaging (DWI)
DWI is highly sensitive to susceptibility artefacts 
and dependent on good acquisition technique. Good 
patient preparation is essential as well as adequate 
training in image reading. T2-shine through effects 
from luminal content, which will present with high 
signal intensity on high b value images and high signal 
intensity in the ADC map, should not to be mistaken 
for true restriction, which will present with high signal 
intensity on high b value images and low signal inten-
sity in the ADC map; or with dense fibrosis, which will 
present with low signal intensity in both high b value 
images and ADC map. While on T2-WI mrTRG the 
Table 1 Re-staging pelvic MR imaging acquisition parameters at 1.5T and 3T Ingenia Philips Healthcare®, Best, The Netherlands
Oblique axial scans  are oriented perpendicularly to the long axis of the rectal wall at tumour location; +Spectral pre-saturation with inversion recovery  is utilised for 
fat saturation













1.5T 3T 1.5T 3T 1.5T 3T 1.5T 3T 1.5T 3T
Echo time (msec) 115 105 115 105 105 100 92 95 10 15
Repetition time (msec) 4206 3943 4206 3943 2433 4672 6779 4140 683 734
Echo train length 17 19 17 19 17 17 – – 5 7
Slice thickness (mm) 3 3 3 3 3 3 4 4 45 4
Gap (mm) 0 0 0 0 0 0 0 0 1 0.8
Matrix 400 x 333 400 x 259 400 x 333 400 x 259 252 × 223 252 x 237 76 × 65 80 × 65 376 x 390 404 × 415
Field-of-view (mm) 200 x 200 200 × 200 200 x 200 200 × 200 200 × 200 200 × 200 200 × 200 200 × 200 300 x 350 300 × 350
In-plane resolution (mm) 0.5 x 0.6 0.5 x 0.6 0.5 x 0.6 0.5 x 0.6 0.8 × 0.8 0.8 x 0.8 2.6 × 3.01 2.5 × 3.1 0.8 x 0.9 0.74 × 0.82
Signal averages 2 2 2 2 2 1 14 13 1 1
B value – – – – – – 1500 2000 – –
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Fig. 1 Primary tumour response. An incomplete/poor  response to NAT may be characterised by (a) little reduction in tumour volume, < 70%. 
b mrTRG3 or higher, translating into the presence of residual intermediate “tumour” signal intensity on T2-WI; c Residual high signal intensity at 
tumour bed on DWI. “Near-complete” responses fall on the good response group and as such, a large reduction in tumour volume may be expected 
but a cutoff is not established (d). e On T2-WI, mrTRG2—scar with “dense fibrosis”—and mrTRG2/3, in which a tiny focus of residual intermediate 
signal may still be visible, are included; f Also, a small residual focus of high signal intensity on high b-value DWI may be admitted. Complete 
responses are characterised by a very large reduction in tumour size, > 70–89% (g). h on T2-WI, they may present as mrTRG1, characterised by 
the presence of a linear/crescenteric 1–2 mm hypointense scar at the endoluminal aspect of the tumour bed or normalisation of the rectal wall; 
they may also present with a positive split scar sign, which includes mrTRG1s and scars with an additional peri-rectal, usually irregular, layer of 
hypointense tissue, separated from the inner linear hypointense linear/crescentic scar by an intermediate signal intensity thickened and partially 
fibrotic muscularis propria; i No high signal intensity at tumour bed on DWI is expected
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proportion of intermediate “tumour” signal at tumour 
bed is taken into consideration, in most studies focus-
ing on response assessment using DWI, assessment is 
binary—restriction indicates viable tumour whereas its 
absence suggests a complete response [28–31]. Also, 
DWI performance is generally evaluated in addition 
to T2-WI, and combined reading appears to perform 
significantly better for most readers [28–31]. Diffusion 
restriction may also be present in radiation-induced 
proctitis or hemorrhage/inflammation post-biopsy and 
when these procedures are performed before MR imag-
ing, the radiologist should be notified. Also, restriction 
may be absent in incomplete responses, and accord-
ing to Lambregts et  al., in clear T2-WI intermediate-
signal residual masses and in T2-hypointense “fibrotic” 
circumferential tumour scars, irrespective of DWI 
findings, the likelihood of viable tumour is very high 
(≥ 80%) [32].
Mucinous tumours have an intrinsically higher ADC 
compared to non-mucinous tumours, making response 
assessment based on DWI more difficult and less reli-
able [33].
An example of a poor tumour response is given in 
Fig. 2.
With respect to mesorectal lymph nodes, lymph 
nodes with incomplete/poor response usually present 
with (Fig. 3a–c):
1. Short axis ≥ 5  mm, which may be associated with a 
likelihood of residual disease up to 63% [12, 34].
2. Residual intermediate “tumour” signal intensity or 
heterogeneous signal intensity on T2-WI, which usu-
ally represents residual macroscopic tumour [34].
Residual high signal intensity on high b value DWI 
with low ADC does not aid in the identification of via-
ble tumour in lymph nodes given it may be observed in 
both lymphoid and tumour tissue.
3. Residual high “mucin” signal on high b-value 
T2-WI  —  Mucinous tumours with lymph node 
involvement present with a higher frequency of 
residual viable tumour after neoadjuvant therapy and 
as such, lymph nodes with visible “mucin” high signal 
intensity on T2-WI at re-staging MR imaging are fre-
quently positive [35].
An example of a poor lymph node response is given 
in Fig. 4.
Involvement of lateral pelvic sidewall lymph nodes 
is more likely to occur in tumours located at the level 
or below the peritoneal reflection, particularly if ≥ T3 
[36]. The lower the location of the primary lesion, the 
higher the risk and in tumours < 4  cm from the anal 
verge, it may exceed 30% [36]. Lymph nodes with mixed 
signal intensity, irregular borders or short axis ≧  5, 7 
or 8  mm (different cutoffs are considered in different 
studies) on staging examinations were associated with a 
higher likelihood of harbouring metastasis [37, 38]. On 
re-staging MR imaging, criteria associated with resid-
ual tumour may be:
1. Size reduction < 33% between pre and post-neoadju-
vant treatment [31].
2. Short axis > 5  mm on post-neoadjuvant therapy MR 
[38].
3.  Residual “tumour” signal intensity or heterogeneous 
signal intensity on T2-W,I just the same as applied to 
mesorectal lymph nodes.
Regarding response of extramural venous inva-
sion (EMVI) to neoadjuvant therapy, Chand et  al.have 
established a specific TRG score for EMVI (mr-vTRG) 
on T2-WI and concluded grades 4 (< 25% fibrosis) and 
5 (minimal fibrosis) were associated with higher local 
recurrence rates (44%) and lower disease-free survival 
(46%) compared to grades 1–3 (50% fibrosis or more)—
9% local recurrence and 88% 3-year disease-free sur-
vival [39]. In our experience assessment of percentage 
of conversion to fibrosis may be difficult but indeed 
residual intermediate “tumour” signal intensity within 
EMVI after neoadjuvant therapy  should signify  via-
ble tumour and a consequent poor or incomplete 
response,  remaining restriction to diffusion supporting 
Table 2 mrTRG and corresponding MR imaging findings [23]
mrTRG—Findings on MR imaging
1. Complete response (linear/crescentic 1–2 mm scar in mucosa or submucosa only, or normalisation of the rectal wall)
2. Good response (dense fibrosis; no obvious residual tumour, signifying minimal residual disease or no tumour)
3. Moderate response (> 50% fibrosis or mucin, and visible intermediate signal)
4. Slight response (little areas of fibrosis or mucin but mostly tumour)
5. No response (intermediate signal intensity, same appearances as original tumour/tumour regrowth)
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it. Although we found no data on the response of 
extranodal tumour deposits, similar criteria may apply.
Given incomplete/poor responders may undergo 
early surgery, it is particularly important that their 
identification is followed by detailed information on 
residual tumour location and relations. The most 
important of all items is the re-evaluation of the cir-
cumferential resection margin (CRM) given a clearance 
of the margin on re-staging high-resolution T2-WI has 
a positive predictive value of up to 90% for a clear mar-
gin at pathology, which may justify a shift towards less 
mutilating surgery [40–42]. On the other hand, if the 
margin is reached by dense hypointense fibrosis, the 
likelihood of tumour at pathology is lower than when 
it is reached by intermediate “tumour” signal intensity 
but is still significant, and as such it should be consid-
ered involved [40–42].
Fig. 2 Incomplete/poor tumour response. A 75 year-old male presented with a low mrT3a mrN0 EMVI + (not shown) CRM-rectal cancer (arrows 
in a–c). He underwent NAT and was re-staged at 12 weeks with MR imaging (d, e) and endoscopy (f). Reduction in size was estimated as < 50%, 
as may be inferred in d vs a. On T2-WI, the tumour scar was composed largely of intermediate signal intensity tissue (d), classified as mrTRG4 with 
absent split scar sign. On high b value DWI (e), a thick layer of high signal intensity was apparent at the endoluminal aspect of the tumour bed 
and a persistent infiltrative lesion was visible on endoscopy (between arrows in f). Patient underwent surgery and specimen was staged as a ypT3 
(extension into mesorectal fat visible at macroscopy in g) N1c (not shown) TRG3 R0. At microscopy, viable tumour was predominantly mucosal/
submucosal (arrow in h) but there were niches of viable tumour cells within the muscularis propria (arrows in i) and also at perirectal fat (not 
shown)
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To identify the complete responders
Approximately 10–25% of patients with locally-advanced 
rectal cancer undergoing NAT prior to surgery achieve 
a pCR [4], escalating to even higher rates when more 
intense RT and/or chemotherapy regimens are employed 
[4].
There are some factors at staging MR that may be 
associated with a higher likelihood of a pCR, namely 
tumour length < 4 cm, tumour circumference < 180º, dis-
tance to anal verge < 45 mm and mrT stage ≤ 3 [43, 44]. 
Also, pCR rate increases with increasing interval to sur-
gery to > 12  weeks [5], which means signs of a clinical 
complete response (cCR) on re-staging MR imaging are 
expected more often with longer intervals as well. Clini-
cal complete response is characterised by a flat white scar 
with telangiectasia on endoscopy (endoscopy 0). At re-
staging MR imaging the following are expected regarding 
the primary tumour (Fig. 1g–i):
1. Very large reduction in tumour size
Volume reduction > 70–89% at T2-WI (T2-hypointense 
“fibrosis” included in the measurements) and > 95–98% at 
DWI (only high signal intensity on high b value images 
measured) associate with a complete response to treat-
ment [45–47].
2. mrTRG 1
Conversion to a linear/crescentic, 1–2 mm scar in the 
mucosa or submucosa or normalisation of the rectal all 
have very high specificity for complete response, in the 
range of 92–98% [48].
3. Positive split scar sign
The split scar sign has a very high specificity (97%) and 
positive predictive value (93/94%) for a sustained com-
plete response [46], but it was not yet validated prospec-
tively. It may be found on high resolution T2-WI and is 
characterised by an organised layered morphologic pat-
tern of the tumour bed after neoadjuvant therapy, com-
posed of an inner thin and regular hypointense band 
corresponding to the fibrosed submucosa; an interme-
diate signal intensity layer immediately underneath it, 
corresponding to a thickened and partially fibrosed mus-
cularis propria; and an outer, irregular, hypointense layer 
of mesorectal fibrosis, which may be absent and usually 
Fig. 3 Mesorectal lymph nodes. An incomplete/poor lymph node response to NAT may be characterised by (a) a short axis ≧5 mm after NAT; b 
residual intermediate “tumour” signal intensity or heterogeneity on T2-WI; c Persistent high signal intensity “mucin” on T2-WI. When a lymph node 
presents with a complete response after NAT, a reduction in short axis superior to 70% at re-staging T2-WI may be observed (d). Also, according 
to ESGAR guidelines, lymph nodes with short axis < 5 mm on re-staging T2-WI (e) should be considered negative. The positive predictive value 
for a complete response in lymph nodes that disappear on T2-WI or DWI (f) is close to 100%. “Near-complete” responders should have no signs of 
persistent disease in lymph nodes and as such criteria are the same as for complete responders
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is in staged ≦ T2 tumours [49]. The split scar sign is 
explained in greater detail in Fig. 5.
4. Absence of high signal intensity on high b value DWI
Complete response on DWI is supported by the 
absence of high signal intensity at high b-value DWI 
images (using normal rectum as reference) [28–31] and 
it may be particularly valuable in small, subcircunferen-
cial scars [32], whereas as previously discussed, in thick, 
circumferential T2-hypointese “fibrotic” responses, the 
likelihood of incomplete response is high even if DWI is 
negative [32].
An example of a complete tumour response is given in 
Fig. 6.
With respect to mesorectal lymph nodes, a complete 
response may present with (Fig. 3d–f):
1. Significant size reduction or disappearance on T2-WI. 
A ≥ 70% short axis reduction or disappearance of 
the LN on T2-WI may indicate ypN0 status in 100% 
of cases [34] and according to ESGAR guidelines, 
LNs < 5  mm after neoadjuvant therapy should be 
assumed as negative [12].
Fig. 4 Incomplete/poor lymph node response. A 65 year-old male presented with a low mrT3b (not shown) mrN1 (arrow in a–c) EMVI− 
CRM+ rectal cancer. He underwent NAT and was re-staged. Lymph node reduction in size was practically inexistent and post-NAT, short axis 
was > 5 mm (d). On T2-WI, the lymph node still looked heterogeneous, with areas of intermediate signal intensity (d). High signal intensity on high 
b value images was less but still present (e) (please note that visibility on high b value post-NAT imaging does not exclude good or even complete 
response). Patient underwent surgery and no residual lymphoid tissue was found within the lymph node in the pathology specimen, only tumour 
surrounded by fibrosis, adjacent to a vessel (f)—patient was therefore staged as a ypT3 N1c TRG3 R0
Fig. 5 The split scar sign is considered present or positive (a) when 
a thin 1–2 mm regular layer of hypointense “fibrosis” is present at 
the endoluminal aspect of the tumour bed (corresponding to the 
fibrosed submucosa), underlined by homogeneous intermediate 
signal (corresponding to a thickened and partially fibrotic muscularis 
propria), covered or not by a usually irregular hypointense layer of 
perirectal fibrosis. In mucinous or mucin-degenerated tumours, the 
middle intermediate signal intensity layer may be replaced with 
homogeneously high signal intensity, corresponding to mucin 
pooling. Whenever the tumour bed is not “organised” in such a 
layered manner (such as with full thickness “black” scars) or whenever 
it is but the inner and/or outer “fibrotic walls” are focally breached, the 
sign should be considered absent/negative (b) [26]
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2. Disappearance on DWI—Absence of visible lymph 
nodes in high b value DWI may be a reliable predic-
tor of ypN0 status [50] but if  high signal persists, a 
complete response may not be excluded.
An example of a complete lymph node response is pro-
vided in Fig. 7.
Lateral pelvic sidewall lymph nodes that shrink to 
4 mm or less in short axis on re-staging MR imaging pre-
sent no risk of local recurrence at 3  years according to 
Ogura et al. [51]. Disappearance or homogenous hypoin-
tensity on T2-WI and no visibility on high b value DWI 
may also favour a complete response.
Regarding response of extramural venous invasion, 
as stated above, mrV-TRG grades 1–3 (50% fibrosis or 
more) are associated with a good response, with only 9% 
LR rate and 88% 3-year DFS [39]. Even without concrete 
data on the subject, it appears reasonable to consider that 
normalisation of vessels or conversion to hypointense 
“fibrotic” signal intensity on T2-WI without high signal 
intensity on DWI would favour a complete response of 
extramural venous invasion, the same applying to extran-
odal tumour deposits.
Complete responders may be offered the possibility 
of entering a specialised surveillance program for organ 
preservation.
Fig. 6 Complete tumour response. A 61 year-old male presented with a low anterior mrT2 (between arrows in a–c) mrN1a (not shown) EMVI− 
rectal cancer. He underwent NAT and was re-staged at 11 weeks (d–f). Reduction in tumour size was considerable, > 80% (d, e). On T2-WI, the 
tumour was reduced to a thin, crescentic, endoluminal hypointense “fibrotic” scar (mrTRG1, split scar sign+) (e). On high b value DWI, no high 
signal intensity was visible (f). Notice how the scar “curled-in” between first and second assessment (e, h, respectively), reducing its depth angle 
significantly (− 35°). Patient is currently on W&W with no signs of disease recurrence at 1 year
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To identify the “near-complete” responders
The criteria presented above are very specific but not 
very sensitive for a complete response. The concept 
of “near-complete response” was introduced more 
recently, driven by the observation that a significant 
proportion of patients presenting with a very good but 
incomplete response at first assessment may convert 
into a cCR if given a longer interval and re-assessment 
[52]. This concept is, however, controversial. The scarce 
literature regarding this group of patients considers that 
they may present with endoscopic gradings 1–2 and/
or up to high-grade dysplasia at histopathology when 
biopsy is performed [52–54]. However, given a negative 
biopsy is not equivalent to a complete clinical response, 
particularly in the presence of clinically residual abnor-
malities, its utility may be put to question [55]. Regard-
ing the MR criteria (Fig. 1d–f ):
mrTRG2‑2/3
Patients with dense fibrosis or with dense fibrosis and 
minimal residual intermediate signal may be considered 
near-complete responders [52, 53].
Small focal area of high signal intensity on high b value DWI
A small focal area of high signal intensity on high b value 
DWI is admissible for a near-complete response [53].
There is no evidence regarding expected tumour size 
reduction for these patients.
Fig. 7 Complete lymph node response. A 42 year-old male presented with a low mrT3a (not shown) mrN1a (arrow in a–c) EMVI− CRM+ rectal 
cancer. He underwent NAT and was re-staged. The positive lymph node showed a pronounced reduction in size after NAT, with a short axis 
reduction of 70% and a short axis < 5 mm (e). On T2-WI, the lymph node became too small to characterise (e). The lymph node was not visible on 
re-staging high b value DWI (f) and disappeared also on T2-WI at 1-year follow up MR imaging (g–i). Patient is currently under W&W with no clinical 
signs of viable local or distant disease
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Fig. 8 “Near-complete” tumour response. An 83 year-old female presented with a low mrT2 (arrows in a, b) mrN1a (not shown) EMVI− CRM− rectal 
cancer. She underwent NAT and was re-staged on endoscopy as grade 1 due to the presence of a red scar (arrow in d), and on MR imaging as 
mrTRG2/3 given tumour bed was now a black scar with a single focus of intermediate signal intensity below endoluminal aspect, a bit displaced 
from the centre (arrow in e), that presented with high signal intensity at high b value DWI (arrow in f). Patient was considered a “near-complete” 
responder and was followed. At 2nd re-staging, an adenomatous mucosal abnormality was observed at the periphery of the scar (arrow in g) and 
patient was considered a grade 2 on endoscopy. On MR imaging, she was now an mrTRG3 due to the expansion of the intermediate signal focus 
(arrow in h), which was also more conspicuous on high b value DWI (arrow in i). Patient underwent abdomino-perineal excision and specimen was 
a ypT3 ypN0 ypEMVI-TRG3 R0. The endoluminal regrowth was apparent on the gross examination of the fresh specimen (arrow in j) and at histology 
was depicted as a focal persistent niche of tumour at the endoluminal aspect of the tumour bed (arrows in k and l) growing in depth. It reached the 
mesorectal fat which was focally invaded (not shown)
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An example of a near-complete tumour response is 
provided in Fig. 8.
Regarding lymph node involvement, the only study on 
near-complete response mentioning lymph nodes con-
siders “suspicious” lymph nodes, whether mesorectal or 
sidewall, should not be present on re-staging MR imaging 
[53]. As such, the same criteria as for complete respond-
ers should be applied (Fig. 3d–f). Although again no data 
was found on the matter, the same may work for EMVI 
and extranodal tumour deposits.
Follow‑up of patients who deferred surgery
Question 1: Can we anticipate a clinical complete response 
is going to be sustained?
There are some signs at re-staging MR imaging that, 
although not validated, may favour a sustained complete 
response:
1. Normalisation of the rectal wall at re-staging MR 
imaging has a 100% specificity for a sustained 
complete response according to the pattern base 
approach by Lambregts et al. [32].
2. A positive split scar sign at first re-staging MR imag-
ing may indicate a sustained complete response for a 
minimum period of 1 year with a specificity of 97%, 
as per our data [49] (Figs. 5, 6).
3. Hypointense “fibrosis” on T2-WI without high sig-
nal intensity on high b value DWI in semicircular 
tumours is, according to Lambregts et al., associated 
with a sustained complete response with a 91% speci-
ficity [32].
Question 2: When we observe a clinical complete response, 
can we anticipate a local regrowth is going to occur later 
on?
There are some signs at re-staging MR imaging that, 
although not validated, may associate with a higher likeli-
hood of a local regrowth:
1. Tumour scar depth angle increase > 21° between 1st 
and 2nd post-NAT MR imaging
The scar depth angle is a measure of tumour bed con-
traction/dilation over time on T2-WI. For patients who 
enroll W&W, a scar depth angle increase of 21° or more 
between the first re-staging MR imaging examination 
(median 10  weeks post-RT) and the following (median 
23  weeks post-RT) signaled a non-sustained complete 
response with a very high specificity (91/94%) [56]. To 
measure it, the central axial slice of the tumour must 
first be chosen using sagittal/coronal planes as refer-
ence. Then, within the central axial slice, the endoluminal 
centre of the scar should serve as pivot while the angle 
lines cross the endoluminal extremities of the scar 
(Fig.  9). For scars taking more than 180º of the rectal 
wall, the angle lines should cross the endoluminal aspect 
of the scar at 180º. The same applies to circumferential 
tumours, in which case the pivot should be placed at the 
endoluminal aspect of the point where it is most inva-
sive (or randomly, if there is none). The most important 
thing to keep in mind is to keep the exact same measure-
ment location between examinations. Figure  8 provides 
an example of tumour depth angle measurements and 
their significance—residual tumour focus grows into the 
lumen of the scar at second assessment, elevating pivot 
for angle measurement. Although it creates a sulc beside 
it, the scar as a whole “opens up”. Please note that these 
results come from a single institution and have not yet 
been validated prospectively [56].
2. Scar thickness > 10  mm at 2nd MR imaging assess-
ment.
For patients who enroll W&W, a scar thick-
ness > 10 mm in the first follow-up examination (median 
Fig. 9 Scar depth angle and thickness measurements should be 
performed on the axial central slice of the tumour. For scar depth 
angle measurements of small (< 180°) tumour scars, the endoluminal 
centre of the scar serves as pivot while the angle lines cross the 
endoluminal extremities of the scar (in blue). In > 180° scars, the 
pivot should also be central but the angle lines should cross the 
endoluminal aspect of the scar at 180° of the rectal circumference 
and no more than that. The same applies to circumferential scars but 
in such cases, the pivot should be placed at the most invasive tumour 
front if there is one, or randomly if there isn´t. The most important 
thing to keep in mind is measuring at the exact same location in both 
first and second post-NAT MR imaging examinations. Scar thickness 
should be measured at pivot level, at the second MR imaging 
assessment. Measurement corresponds to a line that transverses 
tumour scar in depth, perpendicularly to it (in yellow), from inner to 
outer surface, irrespectively of it signal intensity
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23 weeks post-RT) was > 90% specific for a non-sustained 
complete response, irrespective of other findings, accord-
ing to the results of the same study as above [56]. Tumour 
scar thickness measurement should be performed at 
pivot level and corresponds to the in-depth measurement 
of the tumour bed, perpendicularly to it, from its inner 
to outer surface (Fig. 9) (Case in Fig. 8 also presents with 
scar thickness > 10 mm at 2nd assessment).
Question 3: How do we spot a rectal local regrowth?
In upfront clinical complete responders, we may expect a 
bit of scar “contraction” and/or scar “thinning” over time 
[56] but overall, patient preparation and acquisition tech-
nique assured, stable MR imaging findings are good MR 
imaging findings. Any change, even if subtle, should be 
reported but we should always make sure, before inter-
preting the findings, that no endoscopic procedures like 
biopsy, mucosectomy or local excision were performed 
given their potential false positive results. Subtle changes 
may include:
1. Scar thickening Scar thickening may be the first hint 
to a local regrowth and may present before any other 
MR imaging or endoscopic signs of macroscopic 
tumour [56].
2. Depth angle increase Depth angle increase may 
also be present before any obvious signs of a local 
regrowth on MR imaging or endoscopy and in fact 1. 
and 2. may be observed together [56].
More obvious changes indicating a local regrowth are:
3. Intermediate “tumour” signal intensity/heterogeneity 
“de novo” at tumour scar on T2-WI An mrTRG of 5 
should be given when intermediate “tumour” signal 
appears de novo at tumour bed on W&W follow-up.
4. High signal intensity at high b value DWI “de novo” 
A bright spot or area de novo at tumour bed may 
indicate tumour regrowth with high specificity at it 
is particularly important when observed in depth, 
because it will be out of the scope of endoscopy.
Question 4: How do we spot an extra-rectal local regrowth?
Extra-rectal local regrowth is uncommon (3%) [55]. Its 
early detection, whether in lymph nodes, extra-nodal 
tumour deposits or EMVI, is dependent on careful com-
parison with previous examinations.
1. Conformation change, such as apparently “sterilised” 
lymph nodes/tumour deposits that become rounder 
or more irregular.
2. Increase in size, which may be subtle and require 
zoomed-in measurement in multiple planes.
3. Intermediate “tumour” signal intensity/heterogeneity 
on T2-WI de novo.
4. Focus/foci of high signal intensity on high b-value 
DWI de novo.
It is important to state that not all extra-rectal pelvic 
recurrences are clear regrowths. Uncommonly, disease 
may emerge in lymph nodes classified as innocent upon 
staging or as extranodal tumour deposits in a location 
in which only fat/vessels were present before, so carefull 
evaluation of the whole pelvis is imperative (Fig. 10).
Question 5: Upon conversion of a “near-complete” 
response to a clinical complete response, is patient 
prognosis the same compared to upfront clinical complete 
responders?
It is important to state that the management for this 
group of patients is controversial. In the study by Simp-
son et  al. [53], 63% of the “near-complete” responders 
evolved to a cCR within a median time of 8.5  months. 
Compared to upfront clinical complete responders, there 
was an increase in the local regrowth rate from 14 to 18% 
and the disease-free survival dropped from a median 60.5 
to 33  months [53]. Hupkens et  al. [52] reported a 90% 
conversion of “near-complete” responders at first assess-
ment to a clinical complete response if given 6–12 addi-
tional weeks, but with an increase in local regrowth rate 
from 15.9 to 27.1%. No impact on OS was reported in 
either studies [52, 53]. The incidence of distant metasta-
sis is higher in patients with local regrowth (17.8%) than 
in sustained complete responders (4.9%) [55]. In sum-
mary, late complete responses may come at the cost of a 
higher rate of local regrowths, which in turn may be asso-
ciated with a higher incidence of metachronous metasta-
ses. Whether the latter result from upfront differences in 
tumour biology or as a consequence of an uncontrolled 
primary is not yet known.
Re‑staging and follow‑up reporting template
Our proposed re-staging and follow-up reporting tem-
plate is shown in Fig. 11. Please keep in mind that it is a 
mere suggestion and has not been validated in a prospec-
tive and multi-institutional setting.
Compared to the re-staging report template provided 
by ESGAR [10], ours is more complex, time-consuming 
and cumbersome to use because it includes multiple 
methods reported for response assessment and also con-
templates follow-up imaging after re-staging. It involves 
recording thickness, volume, depth angle and their vari-
ation compared to the previous examination, given its 
potential, unvalidated utility in the early prediction of a 
Page 14 of 17Santiago et al. Insights Imaging          (2021) 12:114 
non-sustained complete response, as discussed above. 
Also, our response assessment of the primary tumour 
is based on separate mrTRG, split scar sign and 3-point 
ordinal scale DWI evaluation, while ESGAR recommends 
using a 3-point combined T2-WI/DWI ordinal scale.
Conclusion
“Watch-and-Wait” rectal cancer programs are growing 
around the world and revolve around endoscopy and pel-
vic MR imaging, both for re-staging and patient follow-
up. Radiologists involved in such programs should be 
Fig. 10 Extra-rectal pelvic recurrence. A 62 year-old female with rectal bleeding presented with a 34 mm polyp at colonoscopy which was 
excised revealing a tubulovillous adenoma with moderately differentiated adenocarcinoma, mucinous type, invading the muscularis propria 
with a focally positive margin in depth. No residual tumour was apparent on MR imaging or endoscopy at post-polypectomy assessment (a–d) 
and no extra-rectal suspicious findings were found either (e–h). Patient underwent long course chemoradiation and was followed. Findings 
were stable until the 18th month of follow-up, when irregular, heterogeneous, intermediate signal foci were found cranially to the polypectomy 
scar, within the mesorectal fat, at two different levels (arrows in i, j and k, l). Patient underwent total mesorectal excision and the MR imaging 
findings corresponded to extranodal tumour deposits of intestinal type adenocarcinoma with mucinous areas. The extranodal tumour deposits 
in i, j are shown in the fresh (m) and fixed (n) pathology specimen and at hematoxilin eosin staining both at low (× 2.5) (o) and high (× 200) (p) 
magnification
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Fig. 11 Re-staging and follow-up report template. Our proposed standardised report template is depicted. In blue, a single option should be 
chosen
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familiar with the imaging findings that suggest a poor/
incomplete response, a complete response or a “near-
complete” response and their prognostic implications. 
They should also be equipped for the early detection of 
local regrowths, in depth at tumour bed or extra-rectal in 
particular, given their invisibility at rectoscopy.
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